RNA · Avidity Biosciences Inc

-

Please sign in to comment on RNA

1 Comment

Admin

4 years, 11 months ago

Avidity Biosciences, Inc is currently in a long term downtrend where the price is trading 12.5% below its 200 day moving average.

From a valuation standpoint, the stock is 94.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 71.5.

Avidity Biosciences, Inc's total revenue rose by 48.2% to $2M since the same quarter in the previous year.

Its net income has dropped by 56.5% to $-16M since the same quarter in the previous year.

Finally, its free cash flow fell by 160.5% to $-13M since the same quarter in the previous year.

Based on the above factors, Avidity Biosciences, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US05370A1088
Sector	Healthcare
Industry	Biotechnology

Market Cap	205M
PE Ratio	None
Target Price	25
Beta	0.93
Dividend Yield	None

ABOUT

Avidity Biosciences Inc

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

RNA · Avidity Biosciences Inc

-

Avidity Biosciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Avidity Biosciences Inc using a moving average strategy